1. 70-LB: Lower A1C with Real-Time CGM than with Intermittently-Scanned CGM after One Year—The CORRIDA LIFE Study
- Author
-
LUCIE RADOVNICKÁ, ANETA HÁSKOVÁ, QUOC DAT DO, EVA HOROVA, VENDULA NAVRÁTILOVÁ, ONDREJ MIKES, DAVID CIHLÁR, CHRISTOPHER PARKIN, GEORGE GRUNBERGER, MARTIN PRAZNY, and JAN SOUPAL
- Subjects
Endocrinology, Diabetes and Metabolism ,Internal Medicine - Abstract
We investigated the efficacy of real-time continuous glucose monitoring (rtCGM) and intermittently scanned continuous glucose monitoring (isCGM) on change in A1C. CORRIDA LIFE was a 12 month, real-world, non-randomized trial that assessed the impact of rtCGM (Dexcom G5 or G6) vs. isCGM (FreeStyle Libre 14-Day, Abbott) on A1C and other CGM metrics in adults with T1D. Patients on MDI therapy or CSII with no automatic functions were included. One hundred ninety-one adults with T1D (mean age 40±13 years, A1C 8.1±3.4% [65±14 mmol/mol]) participated in this study; 81 patients initiated rtCGM and 110 initiated isCGM. After 12-months, A1C was significantly lower with rtCGM vs. isCGM (7.1±3.1% [54.1±10.1 mmol/mol] vs. 7.7±3.3% [61.2±12.2 mmol/mol]) , p=0.0001. (Figure 1) The percentage of time in hypoglycemia ( Disclosure L. Radovnická: Consultant; Medtronic, Speaker’s Bureau; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Sanofi. M. Prazny: Advisory Panel; Bayer AG, Consultant; Boehringer Ingelheim International GmbH, Speaker’s Bureau; Abbott Diabetes, Amgen Inc., Eli Lilly and Company, Medtronic, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Novo Nordisk, Sanofi. J. Soupal: Advisory Panel; Abbott Diabetes, Roche Diabetes Care, Speaker’s Bureau; Boehringer Ingelheim International GmbH, Dexcom, Inc., Lilly Diabetes, Medtronic, Novo Nordisk. A. Hásková: None. Q. Do: None. E. Horova: None. V. Navrátilová: None. O. Mikes: None. D. Cihlár: None. C. Parkin: Consultant; Abbott Diabetes, CeQur SA, Dexcom, Inc., LifeScan, MannKind Corporation, Novo Nordisk, Provention Bio, Inc., Roche Diabetes Care. G. Grunberger: Advisory Panel; LifeScan, Nevro Corp., Research Support; Medtronic, Speaker’s Bureau; Abbott Diabetes, Eli Lilly and Company, Novo Nordisk. Funding Ministry of Health, Czech Republic, General University Hospital in Prague
- Published
- 2022